id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-P-0251-0004,FDA,FDA-2002-P-0251,FDA,Notice,N-Notice,2002-12-23T05:00:00Z,2002,12,,,2008-04-12T01:27:49Z,,0,0,090000648049bea4
FDA-2002-P-0251-0003,FDA,FDA-2002-P-0251,"FDA/CDER to PharmaForce, Inc.",Other,LET-Letter,2002-12-20T05:00:00Z,2002,12,,,2008-04-12T01:27:49Z,,0,0,090000648049bea0
FDA-2002-P-0251-0002,FDA,FDA-2002-P-0251,"FDA/CDER to PharmaForce, Inc.",Other,LET-Letter,2002-09-19T04:00:00Z,2002,9,,,2008-04-12T01:27:49Z,,0,0,090000648049be9d
FDA-2002-P-0251-0001,FDA,FDA-2002-P-0251,"FDA/DDM to PharmaForce, Inc.",Other,ACK-Acknowledgement Letter,2002-03-26T05:00:00Z,2002,3,,,2008-04-12T01:27:49Z,,0,0,090000648049be3a